Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Induced Islet Body for Type 1 Diabetes
NCT03728296Phase 1Unknown
- Sponsor
- Allife Medical Science and Technology
- Start
- Jan 2019
- Primary completion
- Jan 2020
- Modality
- Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of autologous induced islet body in type 1 diabetes mellitus (T1D), sponsored by Allife Medical Science and Technology. Primary endpoint: Occurrence of treatment related adverse events at 1 year. Status: unknown.
02
Drugs
autologous induced islet body
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03728296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03728296.